Small-Cap Momentum Watch: Upcoming Catalysts for September 28–October 2
9/27/20269 min read
From operational updates to conference participation, we’ve highlighted the small-cap events that could drive attention this week.
--
Companies Participating at the Lytham Partners Fall 2026 Investor Conference
The Lytham Partners Fall 2026 Investor Conference will take place virtually from September 29–30, 2026. The event will connect micro-cap and small-cap companies with institutional investors through webcast presentations, fireside chats, and one-on-one meetings, featuring companies across healthcare, technology, consumer products, clean technology, and other growth sectors.
NIKI, IVF, IPM, TOON, STEX, SBC, CLNN, CVKD, AENT, SNES, LIQT
Companies Participating at the 5th Annual ROTH Healthcare Opportunities Conference
The 5th Annual ROTH Healthcare Opportunities Conference will take place on September 29, 2026, at The Metropolitan Club in New York City. Hosted by ROTH Capital Partners, the invitation-only event will bring together public and private healthcare companies, institutional investors, and industry specialists for company meetings, expert-led panels, and presentations focused on biotechnology, neuroscience, life science tools, diagnostics, oncology, and medical technology. Discussion topics will include drug pricing and value, insurance coverage, regulatory uncertainty, biotechnology financing constraints, and minimal residual disease monitoring in solid tumors.
CLNN, CRVO, MNOV, RPID, GANX
Other Companies with Material Events This Week
● CAMP – Will host a virtual Analyst Day on September 28, 2026 from 12:00–1:30 p.m. ET featuring presentations and Q&A from executive leadership, patient advocates, and a leading KOL focused on its regulatory RNA-targeting therapeutic pipeline.
● ENSC – Will participate in the 20th Annual Pain Therapeutics Summit in San Francisco from September 28–29, 2026, chaired by Dr. William Schmidt.
● SCWO – Will present new destruction-efficiency data for its AirSCWO supercritical water oxidation technology at WEFTEC 2026 in New Orleans on September 30, 2026 from 2:30–3:00 p.m. CT. The podium presentation will focus on treatment of PFAS, 6PPD-Q, and other emerging pollutants, with management also exhibiting at Booth #2254.
● ALZN – Will present Phase 1/2A pharmacokinetic imaging data for AL001, its novel organic lithium salt, at the ISMRM Workshop on Beyond Protons in Barcelona on September 29, 2026 at 1:35 p.m. local time. The oral presentation will cover lithium pharmacokinetics imaged at 7T.
● NAGE – CEO Rob Fried and CFO Ozan Pamir will participate in Canaccord Genuity’s Well Summit in New York from September 28–30, 2026. Fried will join the “Aging on Trial: Peptides, Hormones, and the Line Between Breakthrough and Hype” panel on September 29 from 11:15 a.m.–12:00 p.m. ET.
● ENHA – Management will participate in Canaccord Genuity’s Well Summit in New York from September 28–30, 2026. CEO Maximillian Martin will appear on the “Aging on Trial” panel on September 29 at 11:15 a.m. ET and will be available for investor meetings.
● SABS – Will present data on SAB-142 at the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan from September 28–October 2, 2026. The presentations will highlight Phase 1 data, mechanism of action, potential for redosing, and early evidence of C-peptide preservation as the program advances through the registrational SAFEGUARD study in Stage 3 type 1 diabetes.
● ATOM – Will present both a paper and a poster at SISPAD 2026 focused on its Mears Silicon Technology platform. On September 29, a poster scheduled from 4:00–6:00 p.m. JST will address off-state leakage and breakdown in GaN-on-silicon devices and compare conventional silicon, high-resistivity silicon, and MST-modified silicon.
● KAPA – President and Chief Scientific Officer Neil Bhowmick will participate in the 24th Annual Discovery on Target conference in Boston from September 28–October 1, 2026 and will moderate the September 30 breakout session “Winning the Race against Cancer Therapy Resistance.”
● SEER – Researchers using the Proteograph platform will present early findings from the PRECISE-SG100K study at the 2026 HUPO World Congress in Singapore from September 27–October 1, 2026. The project integrates deep proteomic profiling with genomic, clinical, and phenotypic data and includes mass-spectrometry-based profiling in 10,000 participants.
● RUBI – September 28, 2026 is the record date for its previously announced stock dividend of 0.50 common shares for each share outstanding. Due-bill trading is expected to run from September 28 through the October 5 distribution date, with the Nasdaq ex-dividend date set for October 6.
● MBRX – Will conclude participation in the AACR Conference on Pancreatic Cancer on September 28, 2026, where new preclinical data show Annamycin’s antitumor activity in pancreatic cancer is partially mediated by CD8+ T-cell cytotoxicity, supporting further evaluation of immune-mediated and combination-treatment mechanisms.
● QTRX – Will highlight progress from its Content Innovation Engine at the European Society for Spatial Biology meeting from September 28–October 1, 2026. Updates will emphasize spatial biology assay development built from the integration of Akoya’s platform and Quanterix’s SIMOA immunoassay capabilities.
● MEDS – Interim Co-CEO Gerald Commissiong will present “What Patients Really Want” at the National Telehealth and Virtual Care Summit in Las Vegas on September 28, 2026 at 9:15 a.m. PT, discussing patient ownership of health data and expansion of telehealth and pharmaceutical access through the Health Lives Here initiative.
● XPL – President and CEO Chris Herald will present at the 38th Annual Mining Forum Americas on September 30, 2026 at 9:40 a.m. MT. The presentation will cover recent drilling results from the Golden Crest gold and Cat Creek critical-metals programs, followed by one-on-one investor meetings.
● CNSY – Will host a business-update conference call and webcast on September 30, 2026 at 8:30 a.m. ET focused on CNSide, its cerebrospinal-fluid diagnostic platform. Management will discuss third-party billing, market access, commercial-team expansion, portfolio expansion, progress against 2026 goals, and growth plans.
● ARRY – Investor relations representatives will participate virtually in the Wolfe Research Utilities, Midstream & Clean Energy Conference on September 29, 2026.
● TACT – Will launch the EPIC TT+ next-generation tabletop gaming printer at the Global Gaming Expo in Las Vegas on September 29, 2026. The product extends EPICENTRAL connectivity to tabletop transaction points such as cashier cages, player clubs, lounges, and redemption areas.
● DCGO – CEO Lee Bienstock and senior Hicuity Health executives will host a webinar on September 29, 2026 at 11:00 a.m. ET to discuss the pending acquisition of Hicuity Health and its tele-ICU, virtual nursing, telemetry monitoring, and other virtual-care services.
● INSE – Will showcase new gaming products and content at G2E in Las Vegas from September 29–October 1, 2026, with a focus on its Interactive, Retail Solutions, Virtual Sports, and Hybrid Dealer businesses and continued North American expansion.
● COPR – Will participate in the 2026 Mining and Energy Expo in Bloomington, Minnesota, from September 29–October 2, 2026. CEO Andrew Brodkey will join an Idaho mining panel on October 1 focused on domestic critical-mineral development, infrastructure, and investment.
● IBIO – Will present new preclinical data on IBIO-610 at the EASD Annual Meeting in Milan on October 1, 2026. In obese non-human primates, a single dose reduced active Activin E by 98% at week 4 and 97% at week 8, supporting further evaluation of a long-acting, infrequently dosed antibody approach.
● SANA – Will present clinical data from an investigator-sponsored first-in-human study of UP421, an allogeneic primary islet-cell therapy engineered with its hypoimmune platform, at EASD 2026 in Milan during the September 28–October 2 meeting. The study involves transplantation into a patient with type 1 diabetes without immunosuppression.
● IPSC – Will present accepted oral abstracts at the EASD Annual Meeting in Milan from September 28–October 2, 2026, covering its iPSC-derived cell-therapy programs for autoimmune diseases including type 1 diabetes.
● FFAI – Will hold its FF EAI “Built in USA” Upstream & Downstream Business Partner Conference Part Two during IROS in Pittsburgh from September 28–30, 2026. A video of the upstream partner and ecosystem co-creation session is scheduled to go live September 29 at 5:00 p.m. PDT.
● TTEC – Will present its CARES quality-intelligence framework at the QATC Annual Conference in Nashville from September 29–October 1, 2026. Andrew Lee’s session, “Beyond the Scorecard,” is scheduled for September 30 from 10:45 a.m.–12:00 p.m. local time.
● IRD – Will participate in the Euretina Innovation Spotlight on September 30, 2026 from 2:20–2:56 p.m. CEST, with Ben Yerxa presenting a clinical-development update on its inherited retinal disease programs. A separate OPGx-BEST1 clinical presentation is scheduled for October 4 and falls outside this week.
● PRQR – Will host a virtual Investor and Analyst educational event on September 30, 2026 at 11:00 a.m. ET focused on NTCP modulation in biliary atresia via liver-targeted RNA editing. Management will review AX-0810 Phase 1 target-engagement data, the rationale for AX-0811, and the clinical framework for upcoming Phase 1 data after dosing the first AX-0811 participant.
● UZX – Is targeting September 30, 2026 as the earliest closing date for the first $5 million tranche of a proposed two-tranche PIPE with Capital Finance. The first tranche is expected to be priced at the higher of $3.00 per share or 105% of the prior trading day’s closing price, with a potential second tranche of up to $15 million tied to identification and acquisition of an AI-hardware manufacturing target.
● ALT – Management will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on September 30, 2026 at 10:30 a.m. ET.
● PHIO – Will present at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania, from September 30–October 1, 2026. CEO Robert Bitterman will provide an update on the completed Phase 1b PH-762 study in cutaneous squamous cell carcinoma and discuss next steps toward further clinical development.
● LXEO – Will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on September 30, 2026 at 9:00 a.m. ET.
● SRFM – Barrett Brown will become President of SurfOS effective September 30, 2026. He will lead go-to-market strategy and commercial expansion for the company’s Palantir-powered AI aviation operating system, with a mandate to accelerate revenue growth and customer adoption.
● SRXH – CEO Kent Cunningham and Eric Jackson, President of the EMJX Platform and Head of Asset Management, will present at the Webull Corporate Connect Series Fintech Investment Webinar on September 30, 2026 at 1:00 p.m. ET.
● CNDT – Will host an Investor Day at The Pierre Hotel in New York City on September 30, 2026 from 8:25 a.m.–12:30 p.m. ET. CEO Harsha Agadi and other executives will review long-term strategy, portfolio priorities, growth opportunities, and take investor questions.
● CTKB – Its next material scientific event begins October 2, 2026 at ICCS 2026 in Miami, where it will showcase Full Spectrum Profiling cytometry solutions. A corporate workshop is scheduled for October 4, so the principal presentation catalyst falls outside this week.
● CBAT – CFO Jiewei Li will present at the Emerging Growth Virtual Equity Conference on October 1, 2026 from 9:30–10:00 a.m. ET. The presentation will cover the Nanjing Phase II ramp, lower unit production costs, Model 32140 shipments, an approximately $96 million Indian customer order, and validation of full-tab 26650 LFP cells for AI data-center backup applications.
● BCHT – Will participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference from October 1–2, 2026, including one-on-one investor meetings. Its formal presentation is scheduled for October 2 at 1:00 p.m. ET.
● EPM – Management will present at Noble Capital Markets’ Emerging Growth Virtual Equity Conference on October 1, 2026 at 11:00 a.m. CT and will host one-on-one investor meetings that day.
● IMSR – CEO Simon Irish will participate on a panel at Guggenheim’s 5th Annual Investing in Advanced Nuclear Energy Conference in New York on October 1, 2026 at 4:45 p.m. ET.
● ATOS – President and CEO Steven Quay will participate as a panelist at the 13th Aging Research and Drug Discovery Meeting at Harvard University in Boston, being held October 1–3, 2026.
● BSIN – CEO Ryan Smith will present and host one-on-one investor meetings at Noble Capital Markets’ Emerging Growth Virtual Equity Conference on October 1, 2026, with the presentation scheduled for 8:30 a.m. ET.
● CHRS – September 30, 2026 at 5:00 p.m. New York time is the record date for a special dividend of contingent value rights tied to the company’s remaining biosimilar-related assets. The CVRs are expected to be distributed on October 7.
● CJMB – Is targeting closing before October 1, 2026 of its $12.5 million cash acquisition of a non-operated working interest in producing Williston Basin oil and gas properties. An independent reserve report estimates attributable PV-10 at $48.1 million on a proved basis and $82.7 million on a total proved, probable, and possible basis.
--
Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.
Disclaimer: Penny stock trading involves substantial risk, so always research every alert before trading, consult with a licensed professional before trading, only invest what you can afford to lose, and always trade with caution. Readers should independently investigate and fully understand all risks before investing. Results listed are NOT typical and individual results may and most likely will vary. Bigtimepennystocks.com and its staff are NOT licensed investment advisors or broker/dealers of any kind.Alerts are not a solicitation or recommendation to buy/sell/hold securities but merely investment ideas that should NEVER serve as the basis of your trading decisions. Bigtimepennystocks.com and its newsletter are for entertainment purposes only. This website and its reports are for general information purposes as we are engaged in the business of marketing and advertising companies for monetary compensation. Any investment decision should be discussed with a financial adviser before taking place. Please invest carefully and read investment information available at the website of the SEC at http://www.sec.gov.
Subscribe to our Free Newsletter
Copyright © 2023 BigTimePennyStocks.com - All Rights Reserved.